Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer

Abstract While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) breast cancer, HER2 + patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor response for two HER2 + breast cancer patients...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Angela M. Jarrett, David A. Hormuth, Vikram Adhikarla, Prativa Sahoo, Daniel Abler, Lusine Tumyan, Daniel Schmolze, Joanne Mortimer, Russell C. Rockne, Thomas E. Yankeelov
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b0d9d0ed140743fbab8a82a362ac28df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!